• Tyrosine kinase inhibitors are the drugs of choice to treat this disease: imatinib, nilotinib, and dasatinib.
  • Treatment with imatinib in newly diagnosed patients triggers a hematologic response in almost 95% of patients, which nilotinib and dasatinib have shown response rates that are slightly higher.
  • If no response is achieved with the aforementioned drugs, treatment consisting of drugs falling under the new generation of tyrosine kinase inhibitors, bosutinib of ponatinib, is begun.
  • In some occasions, patients may be entered into a clinical trial.